Acadia Pharmaceuticals (ACAD) Liabilities and Shareholders Equity (2010 - 2026)

Acadia Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 41.76% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 35.97% YoY), while the FY2025 annual figure was $1.6 billion, up 31.69% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.6 billion, up from $1.6 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.6 billion in Q1 2026, with the low at $587.8 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $855.1 million (2024), against an average of $935.2 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity dropped 17.34% in 2022, then soared 58.59% in 2024.
• Acadia Pharmaceuticals' Liabilities and Shareholders Equity stood at $587.8 million in 2022, then climbed by 27.41% to $749.0 million in 2023, then jumped by 58.59% to $1.2 billion in 2024, then soared by 31.69% to $1.6 billion in 2025, then grew by 2.62% to $1.6 billion in 2026.
• Business Quant data shows ACAD's Liabilities and Shareholders Equity at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.3 billion in Q3 2025.